Literature DB >> 8640233

Sex reversal by loss of the C-terminal transactivation domain of human SOX9.

P Südbeck1, M L Schmitz, P A Baeuerle, G Scherer.   

Abstract

Haploinsufficiency for SOX9 has recently been identified as the cause for both campomelic dysplasia (CD), a human skeletal malformation syndrome, and the associated autosomal XY sex reversal. SOX9 contains a putative DNA-binding motif known as the high-mobility group (HMG) domain characterizing a whole class of transcription factors. We show in cell transfection experiments that SOX9 can transactivate transcription from a reporter plasmid through the motif AACAAAG, a sequence recognized by other HMG domain transcription factors. By fusing all or part of SOX9 to the DNA-binding domain of yeast GAL4, the transactivating function was mapped to a transcription activation (TA) domain at the C terminus of SOX9. This non-acidic TA domain is evolutionarily conserved and rich in proline, glutamine and serine. With one exception, all SOX9 nonsense and frame shift mutations described so far in CD/sex reversal patients lead to truncation of the TA domain, suggesting that impairment of gonadal and skeletal development in these cases results, at least in part, from loss of transactivation of genes downstream of SOX9.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640233     DOI: 10.1038/ng0696-230

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  46 in total

1.  Campomelic dysplasia translocation breakpoints are scattered over 1 Mb proximal to SOX9: evidence for an extended control region.

Authors:  D Pfeifer; R Kist; K Dewar; K Devon; E S Lander; B Birren; L Korniszewski; E Back; G Scherer
Journal:  Am J Hum Genet       Date:  1999-07       Impact factor: 11.025

2.  Genomic characterization of human DSPG3.

Authors:  M Deere; J L Dieguez; S J Yoon; D Hewett-Emmett; A de la Chapelle; J T Hecht
Journal:  Genome Res       Date:  1999-05       Impact factor: 9.043

3.  Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway.

Authors:  S Murakami; M Kan; W L McKeehan; B de Crombrugghe
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

4.  SOX9 interacts with a component of the human thyroid hormone receptor-associated protein complex.

Authors:  Rongjia Zhou; Nathalie Bonneaud; Chao-Xing Yuan; Pascal de Santa Barbara; Brigitte Boizet; Tibor Schomber; Gerd Scherer; Robert G Roeder; Francis Poulat; Philippe Berta; Schomber Tibor
Journal:  Nucleic Acids Res       Date:  2002-07-15       Impact factor: 16.971

5.  Sox9 inhibits Wnt signaling by promoting beta-catenin phosphorylation in the nucleus.

Authors:  Lilia Topol; Wen Chen; Hai Song; Timothy F Day; Yingzi Yang
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

6.  Mechanism of regulatory target selection by the SOX high-mobility-group domain proteins as revealed by comparison of SOX1/2/3 and SOX9.

Authors:  Y Kamachi; K S Cheah; H Kondoh
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

7.  The gene structure and organization of mouse PG-Lb, a small chondroitin/dermatan sulphate proteoglycan.

Authors:  Y Iwata; T Shinomura; K Kurita; M Zako; K Kimata
Journal:  Biochem J       Date:  1998-05-01       Impact factor: 3.857

8.  Deletion of long-range regulatory elements upstream of SOX9 causes campomelic dysplasia.

Authors:  V M Wunderle; R Critcher; N Hastie; P N Goodfellow; A Schedl
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

9.  SOX9 specifies the pyloric sphincter epithelium through mesenchymal-epithelial signals.

Authors:  Brigitte Moniot; Sandrine Biau; Sandrine Faure; Corinne M Nielsen; Philippe Berta; Drucilla J Roberts; Pascal de Santa Barbara
Journal:  Development       Date:  2004-07-07       Impact factor: 6.868

10.  Expression profiling of zebrafish sox9 mutants reveals that Sox9 is required for retinal differentiation.

Authors:  Hayato Yokoi; Yi-Lin Yan; Michael R Miller; Ruth A BreMiller; Julian M Catchen; Eric A Johnson; John H Postlethwait
Journal:  Dev Biol       Date:  2009-01-13       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.